Literature DB >> 29522117

ESR1 and endocrine therapy resistance: more than just mutations.

S Piscuoglio1, C K Y Ng2, B Weigelt3, S Chandarlapaty4, J S Reis-Filho5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29522117      PMCID： PMC5913621          DOI： 10.1093/annonc/mdy081

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  23 in total

Review 1.  Advances in adjuvant hormonal therapy for postmenopausal women.

Authors:  Kathrin Strasser-Weippl; Paul E Goss
Journal:  J Clin Oncol       Date:  2005-03-10       Impact factor: 44.544

2.  Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.

Authors:  Suzanne E Wardell; Matthew J Ellis; Holly M Alley; Koleen Eisele; Todd VanArsdale; Stephen G Dann; Kim T Arndt; Tina Primeau; Elizabeth Griffin; Jieya Shao; Robert Crowder; Jin-Ping Lai; John D Norris; Donald P McDonnell; Shunqiang Li
Journal:  Clin Cancer Res       Date:  2015-05-19       Impact factor: 12.531

3.  Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.

Authors:  Elizabeth L Christie; Sian Fereday; Ken Doig; Swetansu Pattnaik; Sarah-Jane Dawson; David D L Bowtell
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

4.  Genetic interactions in cancer progression and treatment.

Authors:  Alan Ashworth; Christopher J Lord; Jorge S Reis-Filho
Journal:  Cell       Date:  2011-04-01       Impact factor: 41.582

Review 5.  Estrogen receptors as therapeutic targets in breast cancer.

Authors:  Eric A Ariazi; Jennifer L Ariazi; Fernando Cordera; V Craig Jordan
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

6.  Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Authors:  Gaia Schiavon; Sarah Hrebien; Isaac Garcia-Murillas; Rosalind J Cutts; Alex Pearson; Noelia Tarazona; Kerry Fenwick; Iwanka Kozarewa; Elena Lopez-Knowles; Ricardo Ribas; Ashutosh Nerurkar; Peter Osin; Sarat Chandarlapaty; Lesley-Ann Martin; Mitch Dowsett; Ian E Smith; Nicholas C Turner
Journal:  Sci Transl Med       Date:  2015-11-11       Impact factor: 17.956

7.  Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.

Authors:  Britta Weigelt; Iñaki Comino-Méndez; Ino de Bruijn; Lei Tian; Jane L Meisel; Isaac García-Murillas; Charlotte Fribbens; Ros Cutts; Luciano G Martelotto; Charlotte K Y Ng; Raymond S Lim; Pier Selenica; Salvatore Piscuoglio; Carol Aghajanian; Larry Norton; Rajmohan Murali; David M Hyman; Laetitia Borsu; Maria E Arcila; Jason Konner; Jorge S Reis-Filho; Roger A Greenberg; Mark E Robson; Nicholas C Turner
Journal:  Clin Cancer Res       Date:  2017-08-01       Impact factor: 12.531

8.  Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.

Authors:  Sarat Chandarlapaty; David Chen; Wei He; Patricia Sung; Aliaksandra Samoila; Daoqi You; Trusha Bhatt; Parul Patel; Maurizio Voi; Michael Gnant; Gabriel Hortobagyi; José Baselga; Mary Ellen Moynahan
Journal:  JAMA Oncol       Date:  2016-10-01       Impact factor: 31.777

9.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

Authors:  Dan R Robinson; Yi-Mi Wu; Pankaj Vats; Fengyun Su; Robert J Lonigro; Xuhong Cao; Shanker Kalyana-Sundaram; Rui Wang; Yu Ning; Lynda Hodges; Amy Gursky; Javed Siddiqui; Scott A Tomlins; Sameek Roychowdhury; Kenneth J Pienta; Scott Y Kim; J Scott Roberts; James M Rae; Catherine H Van Poznak; Daniel F Hayes; Rashmi Chugh; Lakshmi P Kunju; Moshe Talpaz; Anne F Schott; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

10.  ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

Authors:  Weiyi Toy; Yang Shen; Helen Won; Bradley Green; Rita A Sakr; Marie Will; Zhiqiang Li; Kinisha Gala; Sean Fanning; Tari A King; Clifford Hudis; David Chen; Tetiana Taran; Gabriel Hortobagyi; Geoffrey Greene; Michael Berger; José Baselga; Sarat Chandarlapaty
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330
View more
  2 in total

1.  FoxO3a Inhibits Tamoxifen-Resistant Breast Cancer Progression by Inducing Integrin α5 Expression.

Authors:  Elena Ricci; Mariarosa Fava; Pietro Rizza; Michele Pellegrino; Daniela Bonofiglio; Ivan Casaburi; Marilena Lanzino; Cinzia Giordano; Rosalinda Bruno; Rosa Sirianni; Ines Barone; Diego Sisci; Catia Morelli
Journal:  Cancers (Basel)       Date:  2022-01-02       Impact factor: 6.639

Review 2.  Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?

Authors:  Benoîte Mery; Coralie Poulard; Muriel Le Romancer; Olivier Trédan
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.